On July 16, UnitedHealth rose 8.31% in regular trading, trading at $449.59/share, with turnover of $912 million. The surge was driven by the company's Q2 earnings report released pre-market, which significantly exceeded Wall Street expectations across all key metrics.

UnitedHealth reported Q2 adjusted EPS of $6.38, beating the analyst consensus estimate of $4.86 by 31.28% and representing a 56.37% year-over-year increase from $4.08. Revenue came in at $112.03 billion, surpassing the expected $110.8 billion. The company simultaneously raised its full-year adjusted EPS guidance to $19.50-$20.00, well above the prior target of greater than $18.25 and the Street estimate of $18.49. Additionally, UnitedHealth announced plans to repurchase at least $5 billion in stock during the year, with operating cash flow reaching $11.1 billion in the quarter at 1.9x net income.

The strong results validated improving cost trends in managed care. Sector peers Humana gained 2.24% and Molina Healthcare rose 0.79%, reflecting broader positive sentiment. Multiple institutions including Wells Fargo, KeyBanc, and Piper Sandler had previously raised price targets to the $475-$485 range ahead of the report.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)